U.S. and European regulators announced significant drug decisions affecting multiple companies. The FDA issued a ...

The FDA has awarded Compass Pathways a priority review voucher and rolling submission for its COMP360 psilocybin therapy for treatment-resistant depression, potentially cutting review time to one or ...

After an executive order, the FDA announced it would prioritize the study of some psychedelic drugs for therapeutic use.

The Food and Drug Administration on Friday granted a quick review of three experimental psychedelic drugs meant to treat ...

Some psychedelic drugs, once considered fringe, are getting a step closer to possibly being approved for use as mental health ...

The president ordered cannabis rescheduling and faster psychedelic approvals, but at the same time escalated drug enforcement ...

A bunch of demands on a PowerPoint slide won’t cut it if the Trump administration plans to engage seriously with Tehran's ...

On the economic front, retail sales increased more than expected in March, while February business inventories rose 0.4% ...

The agency issued "national priority vouchers" for the two drugs six days after President Donald Trump promised to facilitate ...

Just days after President Donald Trump signed an executive order fast-tracking the review of psychedelic drugs, more details ...

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced ...